Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy

American Journal of Transplantation

Volumn 2, Issue 1, 2002, Pages 48-56

  Lebranchu, Yvon ^a   Bridoux, Frank ^b   Büchler, Matthias ^a   Le Meur, Yannick ^c   Etienne, Isabelle ^d   Toupance, Olivier ^e   De Ligny, Bruno Hurault ^f   Touchard, Guy ^b   Moulin, Bruno ^g   Le Pogamp, Patrick ^h   Reigneau, Olivier ⁱ   Guignard, Michel ⁱ   Rifle, Gérard ^j  

^a CHU BRETONNEAU   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e HÔPITAL MAISON BLANCHE   (France)

^f CHU Clemenceau   (France)

^g HÔPITAL CIVIL   (France)

^h PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

ⁱ Novartis France Reuil ^*  (France)

^j HÔPITAL DU BOCAGE   (France)

more..

Author keywords

Acute rejection; Anti IL 2 receptor; Anti thymocyte globulin; Basiliximab; Kidney transplantation; Thymoglobulin

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; METHYLPREDNISOLONE; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRAFT SURVIVAL; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NEUROTOXICITY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SERUM SICKNESS; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY TRACT DISEASE;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; COMPARATIVE STUDY; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGE; MYCOPHENOLIC ACID; RACIAL STOCKS; SAFETY; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TISSUE DONORS;

EID: 19244366185     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2002.020109.x     Document Type: Article

References (32)

1. Amlot PL. The clinical and experimental use of monoclonal antibodies to the IL-2 receptor. In: Chatenoud, L, ed. Monoclonal Antibodies in Transplantation. Austin, Texas: R C Landes; 1995, 53-98.
2. Kupiec-Weglinski J, Diamantstein T, Tilney N. Interleukin-2 receptor-targeted therapy - rationale and application in organ transplantation. Transplantation 1988; 46: 785-792.
3. Halloran PF. Immunosuppressive agents in clinical trials in transplantation. Am J Med Sci 1997; 313: 283-288.
4. Wilde MI, Goa KL. Muronomab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 1996; 51: 865-894.
5. Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996; 15: 435-442.
6. Suthanthiran M, Morris RE, Strom TB. Immunosuppressants: cellular and molecular mechanisms of action. Am J Kidney Dis 1996; 28: 159-172.
7. Levey AS, Schmid CH, Lan J. Antilymphocyte antibodies, renal transplantation, and meta-analysis (editorial). Ann Intern Med 1998; 128: 863-865.
8. Szczech LA, Berlin JA, Aradhye S, Grossman RA, Feldman HI. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 1997; 8: 1771-1777.
9. Szczech LA, Berlin JA, Feldman HI for the Anti-Lymphocyte Antibody Induction Therapy Study Group. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Ann Intern Med 1998; 128: 817-826.
10. Brennan DC, Flavin K, Lowell JA et al. A randomized, double-blinded comparison of Thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011-1018.
11. Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R, Veith FJ. Individualization of immediate posttransplant immunosuppression. The value of antilymphocyte globulin in patients with delayed graft function. Transplantation 1988; 45: 406-409.
12. Michael HJ, Francos GC, Burke JF et al. A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients. Transplantation 1989; 48: 805-808.
13. Abramowicz D, Norman DJ, Vereerstraeten P et al. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Kidney Int 1996; 49: 768-772.
14. Soulillou JP, Cantarovich D, Le Mauff B et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175-1182.
15. Amlot PL, Rawlings E, Fernando OL et al. Prolonged action of a chimeric interleukin-2 receptor (CD 25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748-756.
16. Kovarik J, Wolf P, Cisterne JM et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997; 64: 1701-1705.
17. Kovarik JM, Rawlings E, Sweny P et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD 25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc 1996; 28: 913-914.
18. Kovarik JM, Rawlings E, Sweny P et al. Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients. Transplant Int 1996; 9(Suppl. 1): S32-33.
19. Nashan B, Moore R, Amlot P, Schmidt A-G, Abeywickrama K, Soulillou J-P for the CHIB 201 International Study Group. Randomised trial of basiliximab versus placebo for control of cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-1198.
20. Kahan BD, Rajagopalan PR, Hall M, for the United States Simulect®, Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin 2 receptor monoclonal antibody. Transplantation 1999; 67: 276-284.
21. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
22. Meier-Kriesche HU, Ojo AO, Hanson JA, Cibrik DM, Punch JD, Leichtman AB et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70: 1098-1100.
23. Vanrenterghem V, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H, for the steroid dosing Study Group. Double blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352-1359.
24. Mourad G, Garrigue V, Squifflet JP et al. Induction versus non induction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001; 72: 1050-1055.
25. Sollinger H, Kaplan B, Pescovitz M et al. A multicenter, randomized trial of Simulect with early Neoral vs Atgam with delayed Neoral in renal transplantation. A 6 month interim analysis. Transplantation 2001, in press.
26. Ponticelli C, Yussim A, Cambi V et al. on behalf of the "Simulect Phase IV Study Group. A randomized double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001; 72: 1261-1267.
27. Vincenti F, Kirkman R, Light S et al. Interleukin 2 receptor blockade with daclizumab to prevent acute rejection in renal transplantaton. Daclizumab triple therapy Study Group. N Engl J Med 1998; 338: 161-165.
28. Lawen J, Davies EA, Mourad G et al. on behalf of the Simulect International Study Group. Randomized double blind study of immunoprophylaxis with basiliximab, a chimeric anti-IL-2R monoclonal antibody, with MMF containing triple therapy in renal transplantation. Transplantation 2001, in press.
29. Lebranchu Y, Aubert P, Bayle F et al. Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine and Cellcept? One year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. Transplant Proc 2000; 32: 396-397.
30. Cecka JM, Cho YW, Terasaki PI. Analyses of the UNOS Scientific Renal Transplant Registry at three years early events affecting transplant success. Transplantation: 1992; 53: 59-64.
31. Batiuk TD, Bennett WM, Norman DJ. Cytokine nephropathy during antilymphocyte therapy. Transplant Proc 1993; 25(Suppl. 1): 27-30.
32. Hurault de Ligny B, Lebranchu Y. The use of Thymoglobuline induction in renal transplantation: a pharmacovigilance study. Transplant Proc 2000; 32: 351-352.